ANI Pharmaceuticals (ANIP) vs Stoke Therapeutics (STOK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Stoke Therapeutics (STOK) has outperformed ANI Pharmaceuticals (ANIP) over the past year, losing 21.5% versus a loss of 21.5%. Over five years, ANIP leads with a +86.6% price change compared with +1.8% for STOK. ANI Pharmaceuticals is the larger company by market cap ($1.65 billion vs $1.55 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | STOK |
|---|---|---|
| Share price | $71.98 | $23.95 |
| Market cap | $1.65B | $1.55B |
| 1-day change | +0.07% | -1.40% |
| YTD return | -8.88% | -24.54% |
| 1-year return | -21.54% | -21.48% |
| 5-year return | +86.64% | +1.83% |
| P/E ratio (TTM) | 15.58 | — |
| Forward P/E | 7.08 | — |
| EPS (TTM) | $4.62 | $-3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $97.00 | $40.22 |
| 52-week low | $69.58 | $20.32 |
| Distance from 52-week high | -25.79% | -40.45% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +46.96% | +93.99% |
| Average volume | 374.47K | 855.13K |
| Shares outstanding | 22.96M | 64.53M |
| Employees | 970 | 170 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
ANIP vs STOK FAQ
Which is bigger, ANI Pharmaceuticals or Stoke Therapeutics?
ANI Pharmaceuticals (ANIP) is larger, with a market capitalization of $1.65B compared with $1.55B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, ANIP or STOK?
STOK returned -21.48% over the past 12 months, compared with -21.54% for ANIP (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and Stoke Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.